Patrick Walsh compensation by year
ANI PHARMACEUTICALS Summary Compensation Table · the one fiscal year held| Component | FY2020 |
|---|---|
| Salary | $282,760 |
| Bonus | $0 |
| Stock awards | $679,308 |
| Option awards | $0 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $145 |
| Total | $962,213 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ANI PHARMACEUTICALS INC DEF 14A filed April 29, 2021, accession 0001104659-21-057727, and prior-year filings. Open the filing on EDGAR.
How this page was built: the ANI PHARMACEUTICALS INC filed document, accession 0001104659-21-057727. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2021.
Equity holdings
unvested awards at FY2020 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 9,255 | $268,765 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in ANI PHARMACEUTICALS INC's FY2020 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
9 Form 4 lines since the FY2020 proxy (filed April 29, 2021)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-05-13 | Sale | — | 10,000 | $80.63 | 38,432 |
| 2026-05-11 | Sale | — | 3,973 | $80.75 | 48,432 |
| 2026-03-03 | Sale | — | 6,000 | $74.23 | 52,405 |
| 2025-11-13 | Sale | — | 8,643 | $86.88 | 61,405 |
| 2025-11-13 | Gift | — | 3,000 | $0.00 | 58,405 |
| 2025-08-15 | Sale | — | 9,000 | $89.05 | 70,048 |
| 2025-05-22 | Grant or award | — | 4,336 | $0.00 | 79,048 |
| 2024-05-21 | Grant or award | — | 4,410 | $0.00 | 74,712 |
The 8 most recent of 9 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
ANI PHARMACEUTICALS’s named executive officers, FY2020
as the company reported each| Named executive officer | Role | FY2020 total |
|---|---|---|
| Nikhil Lalwani | President and Chief Executive Officer | $3,715,036 |
| Stephen Carey | Senior Vice President, Finance and Chief Financial Officer | $2,754,577 |
| Robert Schrepfer | Former Senior Vice President, New Business Development | $2,658,963 |
| James Marken | Senior Vice President, Operations and Product Development | $1,874,535 |
| Patrick Walsh · this page | Former Interim President and Chief Executive Officer | $962,213 |
| Arthur Przybyl | Former President and Chief Executive Officer | $857,814 |
Board service
ANI PHARMACEUTICALS board · FY2021–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $97,477 | $248,323 | $0 | $0 | $345,800 |
| FY2024 | $101,750 | $272,141 | $0 | — | $373,891 |
| FY2023 | $101,750 | $320,458 | $0 | — | $422,208 |
| FY2022 | $111,315 | $304,183 | $0 | — | $415,498 |
| FY2021 | $111,750 | $297,437 | $0 | — | $409,187 |
Each year as the company reported it in ANI PHARMACEUTICALS's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: ANI PHARMACEUTICALS pays directors a $59,250 cash retainer and $290,000 in equity. As stated in ANI PHARMACEUTICALS's FY2025 proxy.
The full ANI PHARMACEUTICALS compensation record
free company briefThis page is one person within ANI PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ANI PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ANI PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.